Nektar Therapeutics
NKTR
138 hedge funds and large institutions have $85.3M invested in Nektar Therapeutics in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 47 reducing their positions, and 23 closing their positions.
8% more capital invested
Capital invested by funds: $79.3M → $85.3M (+$5.99M)
0.17% more ownership
Funds ownership: 4.86% → 5.02% (+0.17%)
5% less funds holding
Funds holding: 146 → 138 (-8)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
32% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 47
52% less call options, than puts
Call options by funds: $23K | Put options by funds: $48K
Top Buyers
Top Sellers
| 1 |
SCM
Sio Capital Management
New York
|
-$4.02M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.32M |
| 3 |
MAM
Monaco Asset Management
Monaco
|
-$2.86M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.62M |
| 5 |
Millennium Management
New York
|
-$2.11M |
NKTR Hedge Fund Activity: Q3 2023 in Review
138 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2023, worth a combined $85.3M — up 7.6% from $79.3M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of NKTR and 16 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 32 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $12M. The largest seller was Sio Capital Management, exiting entirely with an estimated $4.02M sold.
- 138 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2023, down from 146 in Q2 2023.
- Funds reported $85.3M of Nektar Therapeutics stock for Q3 2023, up 7.6% quarter-over-quarter.
- 16 funds opened new Nektar Therapeutics positions in Q3 2023 and 23 closed out, a net change of -7 holders.
- The largest Nektar Therapeutics buyer in Q3 2023 was RA Capital Management, an estimated $12M added.
- The largest Nektar Therapeutics seller in Q3 2023 was Sio Capital Management, an estimated $4.02M sold.
Based on aggregated 13F filings for Q3 2023.